EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of the Xpert MTB/XDR test for detection of isoniazid, fluoroquinolones, and second-line injectable drugs resistance to Mycobacterium tuberculosis—Anhui Province, China

Ruiqing Zhang iD, Xundi Bao, Fangjin Bao, Chong Teng, Dongfang Xu, Zhou Liu, Yue Li, Bing Zhao, Hui Xia, Ruida Xing, Xichao Ou, Yanlin Zhao

PLOS One · 2025

DOI: 10.1371/journal.pone.0331264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Ruiqing Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chi…. Hauptthemen laut MEDLINE: Isoniazid, Mycobacterium tuberculosis, Fluoroquinolones, Antitubercular Agents. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, Cepheid Investigator-Initiated Study award, Public Health Personnel Training Sopport Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The emergence of drug-resistant tuberculosis (DR-TB) has posed significant challenges to TB control. This study assessed the diagnostic performance of the Xpert MTB/XDR test for detecting drug resistance in TB patients.

Methods

This study analyzed 276 samples collected from clinically suspected MDR-TB patients in Auhui Chest Hospital from 01/03/2022–01/03/2023. The Xpert MTB/XDR test was evaluated for its ability to detect resistance to isoniazid (INH), ethionamide (ETH), fluoroquinolones (FLQ), and second-line injectable drugs (SLIDs) compared with phenotypic drug susceptibility testing (pDST). Specimens were investigated by Sanger sequencing, where the MTB/XDR test and pDST results were inconsistent. Afterward, the clinical performance of the Xpert MTB/XDR test was also evaluated with the composite reference test (pDST + sequencing).

Results

The sensitivity of the Xpert MTB/XDR test against pDST in detecting resistance to INH and FLQ using 276 samples was 95.77% (95% CI: 91.83–98.16) and 93.83% (95% CI: 86.18–97.97), respectively. In contrast, a lower sensitivity of the MTB XDR test in predicting SLIDs and ETH resistance (sensitivity < 75%) compared with pDST was demonstrated in this study. The specificity for detecting all drugs was greater than 90%. Thirty-three samples were retested by sequencing, which identified mutations predicting INH and FLQ resistance, determining whether resistant or not by combining pDST and sequencing results. When considering pDST + sequencing, the sensitivity and specificity of the MTB/XDR assay for INH and FLQ drug targets increased, especially the detection specificity of FLQ has reached 100% (95% CI: 97.95–100).

Conclusion

The Xpert MTB/XDR has high sensitivity and specificity in drug-resistant tuberculosis patients, making it better suited to meet the needs of rapid, sensitive, and accurate detection for drug-resistant tuberculosis in resource-limited settings, and serving as a critical tool for achieving personalized treatment and TB control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoniazidMycobacterium tuberculosisFluoroquinolonesAntitubercular AgentsTuberculosis, Multidrug-ResistantDrug Resistance, Multiple, BacterialHumansChinaMicrobial Sensitivity TestsMaleFemaleAdultSensitivity and SpecificityMiddle Aged

Substanzen

IsoniazidFluoroquinolonesAntitubercular Agents

Autor:innen und Institutionen

  • National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing, China.
  • Microbiological Institute, Anhui Provincial Center for Disease Control and Prevention, Hefei, China.
  • Tuberculosis Prevention and Control Institute, Anhui Provincial Center for Disease Control and Prevention, Hefei, China.
  • Department of Tuberculosis, Beijing Dongcheng District Center for Disease Control and Prevention, Beijing, China.
  • Department of Clinical Laboratory, Anhui Chest Hospital, Hefei, China.

ORCID-Profile: Ruiqing Zhang

Förderung

  • National Key R&D Program of China
  • Cepheid Investigator-Initiated Study award
  • Public Health Personnel Training Sopport Program

Zitieren

APA

Zhang, R., Bao, X., Bao, F., Teng, C., Xu, D., Liu, Z., Li, Y., Zhao, B., Xia, H., Xing, R., Ou, X., & Zhao, Y. (2025). Evaluation of the Xpert MTB/XDR test for detection of isoniazid, fluoroquinolones, and second-line injectable drugs resistance to Mycobacterium tuberculosis—Anhui Province, China. PLOS One. https://doi.org/10.1371/journal.pone.0331264

Vancouver

Zhang R, Bao X, Bao F, Teng C, Xu D, Liu Z, et al. Evaluation of the Xpert MTB/XDR test for detection of isoniazid, fluoroquinolones, and second-line injectable drugs resistance to Mycobacterium tuberculosis—Anhui Province, China. PLOS One. 2025. doi:10.1371/journal.pone.0331264

BibTeX
@article{Zhang2025,
  author = {Zhang, Ruiqing and Bao, Xundi and Bao, Fangjin and Teng, Chong and Xu, Dongfang and Liu, Zhou and Li, Yue and Zhao, Bing and Xia, Hui and Xing, Ruida and Ou, Xichao and Zhao, Yanlin},
  title = {Evaluation of the Xpert MTB/XDR test for detection of isoniazid, fluoroquinolones, and second-line injectable drugs resistance to Mycobacterium tuberculosis—Anhui Province, China},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0331264}
}
Kostenlos starten →